Pioglitazone and bladder cancer

The Lancet

Volumn 378, Issue 9802, 2011, Pages 1543-1544

  Hillaire Buys, Dominique ^a,b   Faillie, Jean Luc ^b,c   Montastruc, Jean Louis ^d,e  

^a LAPEYRONIE HOSPITAL   (France)

^b UNIV MONTPELLIER   (France)

^c NÎMES UNIVERSITY HOSPITAL   (France)

^d TOULOUSE UNIVERSITY HOSPITAL   (France)

^e UNIVERSITÉ DE TOULOUSE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PIOGLITAZONE; PLACEBO;

BLADDER CANCER; CANCER INCIDENCE; CANCER RISK; FOOD AND DRUG ADMINISTRATION; LETTER; PRIORITY JOURNAL; PUBLICATION; TREATMENT DURATION;

EID: 80155171575     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(11)61662-0     Document Type: Letter

References (6)

1. Food and Drug Administration FDA drug safety communication: ongoing safety review of Actos (pioglitazone) and potential increased risk of bladder cancer after two years exposure http://www.fda.gov/Drugs/DrugSafety/ucm226214. htm (accessed Oct 1, 2010).
2. C Piccinni, D Motola, G Marchesini, E Poluzzi Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting Diabetes Care 34 2011 1369 1371
3. European Medicines Agency European Medicines Agency recommends new contra-indications and warnings for pioglitazone to reduce small increased risk of bladder cancer http://www.ema.europa.eu/docs/en-GB/document-library/Press- release/2011/07/WC500109176.pdf (accessed Sept 21, 2011).
4. JA Dormandy, B Charbonnel, DJ Eckland on behalf of the PROactive investigators Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial Lancet 366 2005 1279 1289 (Pubitemid 41416583)
5. J Dormandy, M Bhattacharya, AR van Troostenburg de Bruyn Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive Drug Saf 32 2009 187 202
6. J El-Hage Preclinical and clinical safety assessments for PPAR agonists http://www.docstoc.com/docs/75248557/Preclinical-and-Clinical-Safety- Assessments-for-PPAR-Agonists (accessed Sept 21, 2011).